Sanofi Names Bayer Executive CEO
Sanofi’s board of directors have unanimously appointed Olivier Brandicourt as chief executive officer of Sanofi.
Olivier Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as chairman of the board of management of Bayer HealthCare AG and member of the Executive Council of Bayer AG. Previously, Mr. Brandicourt held numerous positions of increasing responsibility within major global pharmaceutical groups, such as Parke-Davis/Warner-Lambert and Pfizer. Notably, Brandicourt served as a member of Pfizer’s global Executive Leadership Team from 2010 to 2013.
A physician by training, Olivier Brandicourt’s career includes several senior positions in Europe, Canada and the United States. As the head of various key healthcare divisions, he has a broad range of expertise and knowledge of the pharmaceutical industry and has led the launch of numerous new medicines and the completion of strategic acquisitions and integrations.
In agreement with his former employer, Brandicourt will take up his new duties on April 2, 2015.
in October 2014, Sanofi removed Christopher A. Viehbacher as CEO and replaced him on an interim basis with Serge Weinberg,chairman of Sanofi.
Werner Baumann, member of the Board of Management of Bayer AG, will take over the function of chairman at Bayer HealthCare. He will remain a member of the Board of Management of Bayer AG and of the company’s Executive Council. He will also retain responsibility for strategy and portfolio management as well as for the Europe region. He already held leading positions at Bayer HealthCare from 2002 to 2009: initially as Head of Central Administration & Organization and later as a member of the Board of Management and as the subgroup’s Labor Director. Between 2006 and 2009, he actively participated in the integration of Schering AG, Berlin, Germany. Bayer HealthCare comprises the Pharmaceuticals, Consumer Care, Animal Health and Medical Care divisions. Baumann has been a member of the Board of Management of Bayer AG since January 1, 2010. Effective October 1, 2014, he was appointed chief strategy and portfolio officer with responsibility for Corporate Development and Mergers & Acquisitions. He is also responsible for the Europe region. Prior to October 1, 2014, he served as Bayer AG's chief financial officer